RxDoctor Payments Data

Deidra Blanks, MD

Otolaryngology/Facial Plastic Surgery · Fayetteville, NCNPI 1619170529

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $19,525 of the $23,484 with a category attached, or 83.1%. Galderma Laboratories, L.p. accounts for 93.5% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2019 at $11,731 and has fallen 98.8% since, to $140 in 2025.

$23,484in general payments, 2019–2025

Across 84 payments — averaging $279.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Galderma Laboratories, L.p.$22K
  • Merz North America, Inc.$360
  • Regeneron Healthcare Solutions, Inc.$224
  • Sanofi$199
  • GSK$154
  • Aerin Medical Inc.$116
  • plus $480 from 11 others

What the payments were for

  • Speaking & faculty fees$19,52583%
  • Travel & lodging$2,0079%
  • Food & beverage$1,9528%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few otolaryngology/facial plastic surgery providers in North Carolinato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$74,253
Medicare patients
216
Services billed
2,522

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab14$61,809
Epinephrine20$2,965
Scopolamine16$1,592
Ipratropium Bromide25$898
Omeprazole30$559
Fluticasone Propionate27$553
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav14$342
Cephalexin18$193
Famotidine17$138
Montelukast Sodium15$131
Ciprofloxacin Hcl11$107
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen15$97

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Hikma Pharmaceuticals USAEpinephrine$21$2,96520 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few otolaryngology/facial plastic surgery providers in North Carolinaon file to place this against a meaningful peer group, so we don't.

Other otolaryngology/facial plastic surgery in Fayetteville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →